Омела белая Viscum album Mistletoe

Forsch Komplementmed. 2009 Feb;16(1):49-53. doi: 10.1159/000191067. Epub 2009 Jan 30.

[Favourable course of persisting malignant ascites].

[Article in German]

Stange R¹, Jänsch A, Schrag S, Pflugbeil C, Schlodder D, Pandey-Hoffmann U, Uehleke B.

Author information

• 
  ¹Abteilung fur Naturheilkunde, Charité-Universitatsmedizin Berlin, und Immanuel-Krankenhaus Berlin-Wannsee, Königstrasse 63, Berlin, Germany. r.stange@immanuel.de
  

Abstract

Malignant ascites is a frequent complication in oncological diseases. There are no standard therapies for any primary tumour. We report the case of a woman, aged 49 years at the time of primary diagnosis, who suffered from recurrent ascites resulting from liver metastasis of breast cancer. Based on the literature and former experience of our department, mistletoe extract was repeatedly applied intraperitoneally at the occasion of decompressive punctures. The further course of the disease suggests a significant role of mistletoe in achieved symptom control, which also resulted in a considerable improvement in quality of life. The mistletoe solution was well tolerated. Relevant mechanisms of action in addition to the well-known immunomodulating properties of mistletoe could be direct cytotoxic and adjuvant effects to the concomitantly administered chemotherapy of carboplatin/paclitaxel.

[Благоприятный ход упорствовать злокачественным асцитом].

Злокачественным асцитом-частое осложнение в онкологических заболеваний. Нет стандартного лечения для любой первичной опухоли. Мы сообщаем о случае женщина, в возрасте 49 лет на момент первичной диагностики, кто страдал от периодических асцит в результате метастазов печени груди рак. На основе литературы и предыдущего опыта работы нашей кафедры, омела экстракт была неоднократно применена внутрибрюшинно по случаю декомпрессионной проколы. Дальнейшее течение заболевания предполагает значительную роль омела в добились уменьшения симптомов, что также привело к значительному улучшению качества жизни. В омела решение было хорошо переносится. Соответствующих механизмов для действий в дополнение к известным иммуномодулирующие свойства омела могло бы быть прямое цитотоксическое и адъювантной эффектов одновременно проводится химиотерапия карбоплатин/паклитаксел.

Quality of Life and Neutropenia in Patients with Early Stage Breast Cancer: A Randomized Pilot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone

Wilfried Tröger, Svetlana Jezdić, [...], and Miodrag Matijašević

Additional article information

Abstract

Background:

Chemotherapy for breast cancer often deteriorates quality of life, augments fatigue, and induces neutropenia. Mistletoe preparations are frequently used by cancer patients in Central Europe. Physicians have reported better quality of life in breast cancer patients additionally treated with mistletoe preparations during chemotherapy. Mistletoe preparations also have immunostimulant properties and might therefore have protective effects against chemotherapy-induced neutropenia.

Patients and Methods:

We conducted a prospective randomized open label pilot study with 95 patients randomized into three groups. Two groups received Iscador® M special (IMS) or a different mistletoe preparation, respectively, additionally to chemotherapy with six cycles of cyclophosphamide, adriamycin, and 5-fluoro-uracil (CAF). A control group received CAF with no additional therapy. Here we report the comparison IMS (n = 30) vs. control (n = 31). Quality of life including fatigue was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30). Neutropenia was defined as neutrophil counts <1,000/μl and assessed at baseline and one day before each CAF cycle.

Results:

In the descriptive analysis all 15 scores of the EORTC-QLQ-C30 showed better quality of life in the IMS group compared to the control group. In 12 scores the differences were significant (p < 0.02) and nine scores showed a clinically relevant and significant difference of at least 5 points. Neutropenia occurred in 3/30 IMS patients and in 8/31 control patients (p = 0.182).

Conclusions:

This pilot study showed an improvement of quality of life by treating breast cancer patients with IMS additionally to CAF. CAF-induced neutropenia showed a trend to lower frequency in the IMS group.

Keywords: mistletoe thereapy, breast cancer, randomized clinical trial, quality of life, neutropenia

жүктеу/скачать 2.26 Mb.

Достарыңызбен бөлісу: